Literature DB >> 25881832

The amide linker in nonpeptide neurotensin receptor ligands plays a key role in calcium signaling at the neurotensin receptor type 2.

James B Thomas1, Angela M Giddings2, Srinivas Olepu2, Robert W Wiethe2, Keith R Warner2, Philippe Sarret3, Jean-Michel Longpre3, Scott P Runyon2, Brian P Gilmour2.   

Abstract

Compounds acting via the GPCR neurotensin receptor type 2 (NTS2) display analgesia in relevant preclinical models. The amide bond in nonpeptide NTS1 antagonists plays a central role in receptor recognition and molecular conformation. Using NTS2 FLIPR and binding assays, we found that it is also a key molecular structure for binding and calcium mobilization at NTS2. We found that reversed amides display a shift from agonist to antagonist activity and provided examples of the first competitive nonpeptide antagonists observed in the NTS2 FLIPR assay. These compounds will be valuable tools for determining the role of calcium signaling in vitro to NTS2 mediated analgesia.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  FLIPR assay; NTRC-660; NTRC-739; NTS2 receptor; Neurotensin; Pain; SR48692

Mesh:

Substances:

Year:  2015        PMID: 25881832      PMCID: PMC4418200          DOI: 10.1016/j.bmcl.2015.03.083

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  25 in total

1.  Distinct functional characteristics of levocabastine sensitive rat neurotensin NT2 receptor expressed in Chinese hamster ovary cells.

Authors:  M Yamada; M Yamada; A Lombet; P Forgez; W Rostène
Journal:  Life Sci       Date:  1998       Impact factor: 5.037

2.  Identification of the receptor subtype involved in the analgesic effect of neurotensin.

Authors:  I Dubuc; P Sarret; C Labbé-Jullié; J M Botto; E Honoré; E Bourdel; J Martinez; J Costentin; J P Vincent; P Kitabgi; J Mazella
Journal:  J Neurosci       Date:  1999-01-01       Impact factor: 6.167

3.  X-ray structural characterization of SR 142948, a novel potent synthetic neurotensin receptor antagonist.

Authors:  L Quéré; G Longfils; R Boigegrain; B Labeeuw; D Gully; F Durant
Journal:  Bioorg Med Chem Lett       Date:  1998-03-17       Impact factor: 2.823

4.  Interactions of neurotensin with brain dopamine systems.

Authors:  C B Nemeroff; D E Hernandez; D Luttinger; P W Kalivas; A J Prange
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

5.  Agonism, inverse agonism, and neutral antagonism at the constitutively active human neurotensin receptor 2.

Authors:  F Richard; S Barroso; J Martinez; C Labbé-Jullié; P Kitabgi
Journal:  Mol Pharmacol       Date:  2001-12       Impact factor: 4.436

6.  Reduced peptide bond pseudopeptide analogues of neurotensin.

Authors:  S Doulut; M Rodriguez; D Lugrin; F Vecchini; P Kitabgi; A Aumelas; J Martinez
Journal:  Pept Res       Date:  1992 Jan-Feb

7.  Alterations in nociception and body temperature after intracisternal administration of neurotensin, beta-endorphin, other endogenous peptides, and morphine.

Authors:  C B Nemeroff; A J Osbahr; P J Manberg; G N Ervin; A J Prange
Journal:  Proc Natl Acad Sci U S A       Date:  1979-10       Impact factor: 11.205

8.  Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells.

Authors:  N Vita; F Oury-Donat; P Chalon; M Guillemot; M Kaghad; A Bachy; O Thurneyssen; S Garcia; C Poinot-Chazel; P Casellas; P Keane; G Le Fur; J P Maffrand; P Soubrie; D Caput; P Ferrara
Journal:  Eur J Pharmacol       Date:  1998-11-06       Impact factor: 4.432

9.  Low-affinity neurotensin receptor (NTS2) signaling: internalization-dependent activation of extracellular signal-regulated kinases 1/2.

Authors:  Louis Gendron; Amélie Perron; Marcel Daniel Payet; Nicole Gallo-Payet; Philippe Sarret; Alain Beaudet
Journal:  Mol Pharmacol       Date:  2004-09-10       Impact factor: 4.436

10.  Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain.

Authors:  J Mazella; J M Botto; E Guillemare; T Coppola; P Sarret; J P Vincent
Journal:  J Neurosci       Date:  1996-09-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.